Eli Lilly gets BofA target hike as non-obesity pipeline takes focus
Bank of America raised its price target for Eli Lilly (LLY) to $1,557, citing potential upside from non-obesity drugs. The bank increased its valuation multiple and highlighted neuropsychiatric and oncology platforms, with brenipatide as a key focus. Peak sales for brenipatide could reach $10B-$20B, exceeding consensus expectations. Clinical milestones in 2027-28 are seen as potential catalysts.
How this was made
The 30-second read
Why it matters
The BofA upgrade underscores confidence in the company's pipeline beyond obesity drugs, potentially expanding upside.
Market read
Analyst target hikes are a key driver of short‑term price moves for large caps like LLY.
What to watch
Potential regulatory setbacks or competitive pressures in neuropsychiatric space.
Background
Eli Lilly recently highlighted its non‑obesity drug candidates, with several in late‑stage trials.
Ticker impact
Bank of America raised its price target for Eli Lilly to $1,557, up from $1,500, citing upside from non‑obesity pipeline.
upward pressure as investors price in the higher target and pipeline upside
Analyst upgrade with a concrete price target is a fresh catalyst for a large‑cap stock.
Market effects
May lift sentiment for the broader pharma sector as non‑obesity pipelines gain attention.
Positive for US biotech equities, especially large‑cap innovators.
Limited to investors tracking major US drugmakers.
Counterpoint
Target raise could be premature if pipeline milestones are delayed, risking overvaluation.
Key entities
- companyEli Lilly and Co
Pharmaceutical manufacturer with a broad pipeline.
- analystBank of America
Equity research firm issuing the target raise.
